Hematology: A comprehensive approach to study and practice
DOI:
https://doi.org/10.56294/shp202499Keywords:
Hematology, Disorders, leukopenia, Anemia, ThrombocytopeniaAbstract
Blood is a very particular tissue, which has numerous properties. Hematologic diseases encompass a wide range of conditions, including anemias, coagulation disorders, leukemias, lymphomas, and myelomas. Hematology is a vital field that not only focuses on diseases, but has a significant impact on the individual's individual health. The continuous evolution of knowledge and techniques in this discipline promises to improve clinical outcomes and patients' quality of life. General objective: Provide a comprehensive and up-to-date understanding of the components, functions and disorders of blood, as well as the diagnostic methods and treatments available. Aim. Describe a complete approach to study and practice. The methodology used for this research work is framed within a documentary-type bibliographic review, since we are going to deal with topics raised at a theoretical level such as Pediatric Hematology and the most frequent disorders. The technique for data collection consists of electronic materials, the latter such as Google Scholar, PubMed, Science direct, among others, descriptors in health sciences were used. Based on the bibliography found Conclusions: The Article offers a comprehensive and updated vision of blood and its diseases. This resource is essential for health professionals and students. Promoting an evidence-based approach.
References
1. Diaz J., García J, Diaz M. Factores de riesgo asociados a la anemia ferropénica en niños menores de dos años, Revista Electrónica Medimay Oct-Dic [Internet] 2020 [Citado], Vol. 27, número 4: 521 – 530. Disponible en: 568.pdf
2. Auerbach M, Gafter-Gvilli N, Macdougall IC. Intravenousiron: A framework for changing the management of irondeficiency anemia. Lancet Haematol. 2020;7: 2342-2350.
3. WHO Global Anemia estimates. [consultado 30 Nov 2022]. Disponible en: https://1.www.who.int/data/gho/data/themes/topics/anaemia_in_women_and_children
4. Petry N, Olofin I, Hurrell RF, BoyE,Wirth JP, Moursi M, et al. The proportion of anemia associated with irondeficiency in low, medium, and high human developmentindexcountries: a systematicanalysis of nationalsurveys. Nutrients. 2016;8:E693. https://doi.org/10.3390/nu8110693
5. López D. Consideraciones generales para estudiar el síndrome anémico, revisión descriptiva; Arch Med (Manizales) [Internet]. 2021 [Citado]; 21(1):165-181. Disponible en: https://doi.org/10.30554/archmed.21.1.3659.2021
6. Marchi G, Busti F, Zidanes AL, Vianello A, Girelli D. Cobalamindeficiency in the elderly. Mediterr J Hematol InfectDis. 2020; 12(1): e2020043. doi: http://dx.doi.org/10.4084/MJHID.2020.043
7. Sanz-Cuesta T, Escortell-Mayo E, Cura-Gonzalez I, Martín-Fernández J, Riesgo-fuertes R Garrido-elustondo S, et al. Oral versus intramuscular administration of vitamin B12 for vitamin B12 deficiency in primarycare: a pragmatic, randomised, non-inferiorityclinical trial (OB12). BMJ Open. 2020; 10: e033687. doi : 10.1136/bmjopen-2019-033687
8. Means Jr RT, Fairfield KM. Clinical manifestations and diagnosis of vitamin B12 and folate deficiency. UpToDate. 2021. https:// www.uptodate.com/contents/clinical-manifestations-and-diagnosis-of-vitamin-b12-and-folate-deficiency/print 2/
9. MeansJr RT, Fairfield, KM. Causes and pathophysiology of vitamin B12 and folatedeficiencies. UpToDate. 2022. https://www. uptodate.com/contents/causes-and-pathophysiology-of-vitamin-b12-and-causes and pathophysiology of vitamin B12 and folatedeficiencies
10. Krezelewski D, Catt L. Prescribing Interface Advisor In consultation with Dr Moorby – HaematologistSherwoodForest Hospital. Vitamin B12 treatmentguideline. (Nottinghamshire AreaPrescribingCommittee) NHS; November 2018 ReviewNovember 2021.
11. Glader B, Means RT. Diagnosis and management of glucose6-phosphate dehydrogenasedeficiency. [Internet]. UpToDate. Disponible en: https://www.uptodate.com/contents/diagnosisand-management-of-glucose-6-phosphate-dehydrogenase g6pddeficiency?sectionName=EPIDEMIOLOGY&topicRef=5927&an chor=H143332893&source=see_link#H143332893
12. Bardón Cancho EJ, García-Morín M, Beléndez C, Velasco P, Benéitez D, Ruiz-Llobet A, et al; en representación del grupo de trabajo de Eritropatología de la Sociedad Española de Hematología y Oncología Pediátricas (SEHOP). Update of the Spanishregistry of haemoglobinopathies in children and adults. Med Clin (Barc). 2020; 155(3): 95-103.
13. Román-Hernández C, Bonet-de Luna C. Déficit de glucosa6-fosfato deshidrogenasa: la peregrinación del chico con color. Rev Pediatr Aten Primaria. 2016; 18: 349-54.
14. Bello-Gutiérrez P, Mohamed-Dafa L. Déficit de glucosa-6-fosfato deshidrogenasa: revisión a propósito de un caso. Rev Pediatr Aten Primaria. 2015; 17: 361-8.
15. Cappellini MD, Fiorelli G. Glucose-6-phosphate dehydrogenasedeficiency. Lancet. 2008; 371: 64-74
16. Martínez L, Villegas J, Herrera L, Correa M, Gálvez K, Hernández A, et al. Caracterización de pacientes con anemia de células falciformes en Medellín, Colombia. Medicina Interna de México[Internet]. 2022[acceso: 23/10/2024]; 38(5):1012-1018. Disponible en: https://www.medigraphic.com/pdfs/medintmex/mim-2022/mim225e.pdf.
17. MarchecoTeruel B, Suárez Besil B, Gómez Martínez M, Collazo Mesa T, Pérez Rodríguez J, García Heredia M, et al. Impacto del programa de prevención de anemia por hematíes falciformes en Cuba: 1982-2016. Anales de la Academia de Ciencias de Cuba [Internet]. 2018 [acceso:23/10/2024]; 8 (1). Disponible en: https://revistaccuba.sld.cu/index.php/revacc/article/view/440
18. NguepnkepKubong L, Cabral NyaBiapa P, Chetcha B, Yanou-Njintang N, Moor Ama VJ, Anatole Pieme C. Relationship between Higher Atherogenic Index of Plasma and Oxidative Stress of a Group of Patients Living with Sickle Cell Anemia in Cameroon. AdvHematol. 2020; 2020: 9864371. DOI: https://doi.org/10.1155/2020/9864371
19. Cruz VH, Rosales RS, Lores GM, Roque C, Rodríguez LY. Perfil lipídico y estado redox asociados al estado vaso-oclusivo en la anemia drepanocítica. Rev Cubana InvBiomed[Internet]. 2022[acceso:23/10/2024]; 42(1):e2449.Disponible en: https://revibiomedica.sld.cu/index.php/ibi/article/view/2449 10.
20. Svarch E, Hernández P, Ballester JM. La drepanocitosis en Cuba. Rev Cubana HematolInmunol Hemoter [Internet]. 2004 [acceso: 23/10/2024];20(2): [aprox. 10p]. Disponible en: http://scielo.sld.cu/scielo.php?script
21. Jackson ME, Baker JM. HemolyticDisease of theFetus and Newborn: Historical and CurrentState. ClinLabMed. [Internet] 2021 [citado 2024 Sep 03];41(1):133-151. Disponible en: https://pubmed.ncbi.nlm.nih.gov/33494881/
22. Amezcua Manuel. Enfermeras omitidas por la historia. IndexEnferm. [Internet] 2021[citado 2024 Sep 03];30(3): 277-278. Disponible en: https://scielo.isciii.es/scielo.php?script=sci_arttext&pid=S113212962021000200027
23. Tugcu AU, Ince DA, Turan O, Belen B, Olcay L, Ecevit A. Hemolytic anemia causedby non-D minorbloodincompatibilities in a newborn. Pan AfrMed J. [Internet]. 2019 [citado 14 Abril 2024];33:262. Disponible en: https://pubmed.ncbi.nlm.nih.gov/31692740/
24. Das S, Chakrabarty R, Zaman R. Immunohematological and clinical characterizations of mixed autoimmune hemolytic anemia. Asian J Transfus Sci. 2018;12: 99-104. https://doi.org/10.4103/ajts. AJTS_105_17
25. Chou ST, Alsawas M, Fasano RM, et al. American Society of Hematology 2020 guidelinesforsicklecelldisease: transfusionsupport. BloodAdv. 2020;4(2):327-55. DOI: 10.1182/ bloodadvances.2019001143
26. Vardiman JW, Thiele J, Arber DA, Brunning RD, Borowitz MJ, Porwit A, et al. The 2008 revision of the World Health Organiza tion (WHO) classification of myeloid neoplasms and acute leukemia: Rationale and important changes. Blood. 2009;114:937-51.OMS
27. Fernández-Delgado ND, Fundora-Sarraf TA, Macías-Pérez I. Policitemia Vera. Experiencias en el diagnóstico y tratamiento en el Instituto de Hematología e Inmunología Rev Cubana Hematol Inmunol Hemoter. 2011:27(1)77-90.
28. Kiladjian JJ, Cassinat B, Chevret S, Turlure P, Cambier N, Murielle R, et al.
29. Pegylated interferon a- 2a induces complete hematologic and molecular responses with low toxicity in polycythemia vera. Blood. 2008; 112:3065-72.
30. Tefferi A. Annual clinical updates in hematological malignancies: a continuing medical education series: polycythemia vera and essential thrombocythemia: 2011 update on diagnosis, risk-stratification, and management. American Journal of Hematology. 2011;86(3):292-301.
31. Cooper N, Cuker A, Bonner N, Ghanima W, Provan D, Morgan M, et al. Qualitative study to support the content validity of the immune thrombocytopenia (ITP) Life Quality Index (ILQI). Br J Haematol. 2021 Aug;194(4):759-66. PMID: 34263940.
32. Kuter DJ, Mathias SD, Rummel M, Mandanas R, Giagounidis AA, Wang X, Deuson RR. Health-related quality of life in nonsplenectomized immune thrombocytopenia patients receiving romiplostim or medical standard of care. Am J Hematol. 2012 May;87(5):558-61. PMID: 22460421.
33. Cooper N, Kruse A, Kruse C, Watson S, Morgan M, Provan D, et al. Immune thrombocytopenia (ITP) World Impact Survey (I-WISh): Impact of ITP on health-related quality of life. Am J Hematol. 2021 Feb 1;96(2):199-207. PMID: 33107998.
34. Cheng G, Saleh MN, Marcher C, et al. Eltrombopag for management of chronic immune thrombocytopenia (RAISE): a 6-month, randomised, phase 3 study. Lancet. 2011; 377(9763): 393–402. [PubMed: 20739054]
35. Bussel JB, Provan D, Shamsi T, et al. Effect of eltrombopag on platelet counts and bleeding during treatment of chronic idiopathic thrombocytopenic purpura: a randomised, double-blind, placebocontrolled trial. Lancet 2009; 373: 641-8.
36. Ramos CA, Grover NS, Beaven AW, Lulla PD, Wu MF, Ivanova A, … & Savoldo B. Anti-CD30 CAR-T Cell Therapy in Relapsed and Refractory Hodgkin Lymphoma. J Clin Oncol. 2020 Nov 10;38(32):3794-3804.
37. Cooper N, Kruse A, Kruse C, Watson S, Morgan M, Provan D, et al. Immune thrombocytopenia (ITP) World Impact Survey (I-WISh): Impact of ITP on health-related quality of life. Am J Hematol. 2021 Feb 1;96(2):199-207. PMID: 33107998
38. Zinzani, P. L., Ramchandren, R., Santoro, A., Paszkiewicz-Kozik, E., Gasiorowski, R., Johnson, N. A., ... & Kuruvilla, J. (2022). Quality-of-life analysis of pembrolizumab vs brentuximab vedotin for relapsed/refractory classical Hodgkin lymphoma. Blood advances, 6(2), 590-599.
39. Spinner, M. A., Sica, R. A., Tamaresis, J. S., Lu, Y., Chang, C., Lowsky, R., & Arai, S. (2023). Improved outcomes for relapsed/refractory Hodgkin lymphoma after autologous transplantation in the era of novel agents. Blood Journal, blood-2022018827.
40. Ramos CA, Grover NS, Beaven AW, Lulla PD, Wu MF, Ivanova A, … & Savoldo B. Anti-CD30 CAR-T Cell Therapy in Relapsed and Refractory Hodgkin Lymphoma. J Clin Oncol. 2020 Nov 10;38(32):3794-3804.
41. Elghetany MT, Punia JN, Marcogliese AN. Inherited Bone Marrow Failure Syndromes: Biology and Diagnostic Clues. Clinics in Laboratory Medicine. 2021 [acceso 17/03/2022];41: 417–431. Disponible en: https://pubmed.ncbi.nlm.nih.gov/34304773/
42. Rego YH, Noda G, Pita AMS. Características citomorfológicas de las alteraciones plaquetarias cuantitativas y su relación con otras alteraciones celulares. Revista Cubana de Hematología, Inmunología y Hemoterapia. 2020 [acceso 15/03/2022];36. Disponible en: http://www.revhematologia.sld.cu/index.php/hih/article/view/992/1020
43. Gouache E, Greze V, Strullu M, Saultier P, Fennetau O, Gandemer V, et al. Leukemia Cutis in Childhood Acute Myeloid Leukemia: Epidemiological, Clinical, Biological, and Prognostic Characteristics of Patients Included in the ELAM02 Study. Hemasphere. 2018 [acceso 15/03/2022];2(5):e141. Disponible en: https://pubmed.ncbi.nlm.nih.gov/30887005/ 7. Cabrero Hernández M, Andión Catalán M, Molina Angulo B, Castillo Robleda A, Madero López L. Skin infiltration as a presenting sign of congenital leukaemia: Presentation of two cases. Anales de Pediatría. 2020 [acceso 15/03/2022];92:106-08. Disponible en: https://www.analesdepediatria.org/en-skin-infiltration-as-presenting-sign-articuloS2341287920300041
44. Martínez F. Factores de riesgo de Leucemia en el Recién Nacido - Relaped. 2020 [acceso 24/03/2022];2020:1(2). Disponible en: https://relaped.com/factores-de-riesgo-de-leucemiaen-el-recien-nacido/
45. Instituto Nacional de Enfermedades Neoplásicas. Neoplásicas recibe alrededor de 700 nuevos casos de cáncer infantil. INEN. 2018 [acceso 24/03/2022]. Disponible en: https://portal.inen.sld.pe/neoplasicas-recibe-alrededor-de-700-nuevos-casos-de-cancerinfantil/
46. Instituto Regional de Enfermedades Neoplásicas del Sur. Registro de cáncer hospitalario IREN - SUR, 2015. IREN - SUR. 2015 [acceso 24/03/2022]. Disponible en:http://www.irensur.gob.pe/index.php/control-del-cancer/epidemiologia. 12. Adawiyah R, Hangara DS. Congenital Leukemia With AML-M4 And Leukemia Cutis: A Case Report. NVEO-Natural Volatiles & Essential Oils Journal | NVEO. 2022 [acceso 20/03/2022];496-507. Disponible en: https://www.nveo.org/index.php/journal/article/view/4532
47. Papaemmanuil E, Gerstung M, Bullinger L, Gaidzik VI, Paschka P, Roberts ND, et al. Genomic Classification and Prognosis in Acute Myeloid Leukemia. The New England Journal of Medicine. 2016 [acceso 13/03/2022];374(23):2209221. Disponible en: https://pubmed.ncbi.nlm.nih.gov/27276561/
48. Welch JS, Ley TJ, Link DC, Miller CA, Larson DE, Koboldt DC, et al. The origin and evolution of mutations in acute myeloid leukemia. Cell. 2012 [acceso 18/03/2022];150(2):264-78. Disponible en: https://pubmed.ncbi.nlm.nih.gov/22817890/
49. Martínez-Leboráns L, Victoria-Martínez AM, Torregrosa-Calatayud JL, Alegre de Miquel V. Leukemia cutis:a report of 17 cases and a review of the literature. Actas Dermosifiliogr. 2016 [acceso 18/03/2022];107(9):e65-e69. Disponible en: https://pubmed.ncbi.nlm.nih.gov/27210518/
50. Kristinson SY, Minter AR, Korde N, Tan E, Landgren O. Bone disease in multiple myeloma and precursor disease: novel diagnostic approaches and implications on clinical management. Expert Rev Mol Diagn. 2011 Jul; 11(6): 593–603.
51. Cavo M, Rajkumar SV, Palumbo A, Moreau P, Orlowski R, Bladé J, et al. International Myeloma Working Group consensus approach to the treatment of multiple myeloma patients who are candidates for autologous stem cell transplantation. Blood. 2011 Jun 9; 117(23): 6063–73.
52. Lonial S, Anderson KC. Association of response endpoints with survival outcomes in multiple myeloma. Leukemia. 2014 Feb; 28(2): 258–68.
53. Podar K, Tai YT, Hideshima T, Vallet S, Richardson PG, Anderson KC. Emerging therapies for multiple myeloma. Expert Opin Emerg Drugs. 2009 Mar;14(1):99-127
54. Larson D, Kyle RA, Rajkumar SV. Prevalence and Monitoring of Oligosecretory Myeloma. N Engl J Med. 2012 Aug 9;367(6):580-1.
55. Rajkumar SV. Treatment of multiple myeloma. Nat Rev Clin Oncol. 2011 Apr 26;8(8):479-91
56. Surendran S, Adaikalakoteswari A, Saravanan P, Shatwaan IA, et al. An update on vitamin B12-related gene polymorphisms and B12 status. Genes Nutr 2021; 13 (1): 1-35. doi: 10.1186/s12263-018-0591-9
57. Alpers DH, Russell-Jones G. Gastric intrinsic factor: The gastric and small intestinal stages of cobalamin absorption. A personal journey. Biochimie 2013; 95 (5): 989-94. https:// doi.org/10.1016/j.biochi.2022.12.006
58. Elshinawy M, Gao HH, Al-Nabhani DM. Clinical and molecular characteristics of imerslund-gräsbeck syndrome: First report of a novel Frameshift variant in Exon 11 of AMN gene. Int J Lab Hematol 2021; 43 (5): 1009-15. doi: 10.1111/ijlh.13473
59. Kumbar N. Neurologic aspects of cobalamin (B12) deficiency. Handb Clin Neurol 2014: 120: 915-926. doi: 10.1016/ B978-0-7020-4087-0.00060-7
60. Villegas A, Arrizabalaga B, Bonanad S, Colado E, Gaya A, González A, et al. Consenso español para el diagnóstico y tratamiento de la hemoglobinuria paroxística nocturna. Medicina Clínica. [Internet] 2016 Mar 18;146(6):278.e1-278.e7. Disponible en https://doi.org/10.1016/j.medcli.2015.12.012
61. Blanco S, Frutos M, Carrizo L, Nogués N, Gallego SV. Establishment of the first platelet-donor registry in Argentina. Blood Transfus. 2020; 18 (4): 254-260.
62. Paredes V, Cuba J, Merino A. Conocimientos y actitudes hacia la donación voluntaria de sangre en estudiantes de una universidad pública de Lima-Perú. Ágora Rev Cient. 2021; 8 (1): 23-28.
63. MINSAL. Actualización sobre donación de sangre en Chile [Internet]. 2019 [citado 20 de marzo de 2023]. Disponible en: https:// www.sochihem.cl/bases/arch1897.pdf
64. WHO. Global status report on blood safety and availability 2018. Geneva: World Health Organization; [Internet] 2021. Available in: https://www.who.int/publications/i/item/9789240051683
65. Torrent-Sellens J, Salazar-Concha C, Ficapal-Cusí P, Saigí-Rubió F. Using digital platforms to promote blood donation: motivational and preliminary evidence from Latin America and Spain. Int J Environ Res Public Health. 2021; 18 (8): 4270.
Published
Issue
Section
License
Copyright (c) 2024 Anelys García Salgado, Hanoi Mijares Medina, Anadely Gámez Pérez, Elena López González (Author)
This work is licensed under a Creative Commons Attribution 4.0 International License.
The article is distributed under the Creative Commons Attribution 4.0 License. Unless otherwise stated, associated published material is distributed under the same licence.
